Rhino-Orbital-Cerebral Mucormycosis in a Post-COVID-19 Patient from Peru

IF 1 Q4 INFECTIOUS DISEASES
Linda Ponce-Rosas, J. Gonzales-Zamora, Nelson Diaz-Reyes, Oliver Alarco-Cadillo, J. Alave-Rosas
{"title":"Rhino-Orbital-Cerebral Mucormycosis in a Post-COVID-19 Patient from Peru","authors":"Linda Ponce-Rosas, J. Gonzales-Zamora, Nelson Diaz-Reyes, Oliver Alarco-Cadillo, J. Alave-Rosas","doi":"10.1155/2022/2537186","DOIUrl":null,"url":null,"abstract":"Mucormycosis has been reported increasingly in patients affected by COVID-19, especially in India where the first cases were described. In Latin America, there is limited information about this association, mainly coming from Brazil, Mexico, and Peru. Herein, we report the case of a 66-year-old female that presented with rhino-orbital-cerebral mucormycosis, diabetic ketoacidosis, and COVID-19. The patient had the compromise of all the sinuses, orbital invasion, and intracranial extension. Isavuconazole was promptly initiated because amphotericin B was not available. She had a single open surgical debridement of necrotic tissues at the beginning of the diagnosis then multiple manual sessions to clear the residual or recurrent disease during approximately 5 months. Isavuconazole was effective and well-tolerated for 10 months without side effects. We highlight the importance of considering mucormycosis in post-COVID-19 patients with uncontrolled diabetes. The report emphasizes the favorable outcome of isavuconazole as an alternative therapy.","PeriodicalId":9608,"journal":{"name":"Case Reports in Infectious Diseases","volume":"129 1","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2022-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Infectious Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2022/2537186","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 2

Abstract

Mucormycosis has been reported increasingly in patients affected by COVID-19, especially in India where the first cases were described. In Latin America, there is limited information about this association, mainly coming from Brazil, Mexico, and Peru. Herein, we report the case of a 66-year-old female that presented with rhino-orbital-cerebral mucormycosis, diabetic ketoacidosis, and COVID-19. The patient had the compromise of all the sinuses, orbital invasion, and intracranial extension. Isavuconazole was promptly initiated because amphotericin B was not available. She had a single open surgical debridement of necrotic tissues at the beginning of the diagnosis then multiple manual sessions to clear the residual or recurrent disease during approximately 5 months. Isavuconazole was effective and well-tolerated for 10 months without side effects. We highlight the importance of considering mucormycosis in post-COVID-19 patients with uncontrolled diabetes. The report emphasizes the favorable outcome of isavuconazole as an alternative therapy.
秘鲁1例covid -19后患者的鼻-眶-脑毛霉菌病
在受COVID-19影响的患者中,毛霉病的报告越来越多,特别是在第一批病例被描述的印度。在拉丁美洲,关于这种关联的信息有限,主要来自巴西、墨西哥和秘鲁。在此,我们报告了一位66岁的女性,她表现为鼻-眶-脑毛霉病、糖尿病酮症酸中毒和COVID-19。患者所有鼻窦受损,眼眶侵犯,颅内扩张。由于两性霉素B无法获得,立即开始使用依唑康唑。在诊断之初,她接受了一次开放性手术清除坏死组织,然后在大约5个月的时间里多次手工清除残留或复发的疾病。Isavuconazole有效且耐受性良好,10个月无副作用。我们强调在covid -19后合并未控制的糖尿病患者中考虑毛霉病的重要性。该报告强调了异戊康唑作为替代疗法的良好结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
64
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信